Polaris: Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)

(marketscreener.com) TAIPEI, Taiwan and SAN DIEGO, Dec. 04, 2023 -- Polaris Group , today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that combines ADI-PEG 20 or placebo with traditional chemotherapy as systemic treatment in the second or third line for LMS. The decision to move forward with this global, Phase 3 trial is based...https://www.marketscreener.com/quote/stock/POLARIS-GROUP-45428601/news/Polaris-Group-Initiates-Phase-3-Trial-First-Patient-Successfully-Dosed-with-ADI-PEG-20-Placebo-plus-45493378/?utm_medium=RSS&utm_content=20231204